A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a randomised, double‐blind, two‐arm, parallel group, single‐dose study to comparethe pharmacokinetics, safety, tolerability, and immunogenicity of ixekizumab (SB35 andTaltz) in healthy participants. Participants will be randomised 1:1 to receive a singledose of either SB35 or Taltz. All investigational products (IPs) will be administeredsubcutaneously in the abdomen.
Epistemonikos ID: 2d8b0bb775a61100cf0202996400e66c837fb405
First added on: Aug 27, 2026